CEO Bobak Azamian was paid $6,617,979 in fiscal year 2025, ↓ down 16.2% from fiscal year 2024, the 27th percentile of its disclosed peer group (SEC filing 0001819790-26-000028 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,617,979 ↓ Bobak Azamian total, FY2025 | 27th CEO pay percentile vs peers | 26:1 CEO-to-median pay ratio | 99.31% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
TARS's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Bobak Azamian | $726,333 | $0 | $2,648,284 | $2,651,487 | $555,700 | $0 | $36,175 | $6,617,979 |
| President, Chief Executive Officer and Board Chairman | ||||||||
| Aziz Mottiwala | 529,250 | — | 983,361 | 984,518 | 260,100 | 0 | 32,300 | 2,789,529 |
| Chief Commercial Officer | ||||||||
| Jeffrey Farrow | 541,667 | 0 | 893,961 | 895,011 | 264,900 | 0 | 82,078 | 2,677,617 |
| Chief Financial Officer and Chief Strategy Officer | ||||||||
| Seshadri Neervannan | 547,000 | 0 | 893,961 | 895,011 | 267,300 | 0 | 24,900 | 2,628,172 |
| Chief Operating Officer | ||||||||
| Bryan Wahl | 500,833 | 0 | 893,961 | 895,011 | 245,500 | 0 | 24,900 | 2,560,205 |
| General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Bobak Azamian | $6,617,979 | $7,896,192 | $3,130,332 | ↓ −1,278,213 |
| Aziz Mottiwala | 2,789,529 | 3,138,862 | — | ↓ −349,333 |
| Jeffrey Farrow | 2,677,617 | 3,232,926 | 3,991,830 | ↓ −555,309 |
| Seshadri Neervannan | 2,628,172 | 3,194,689 | 1,741,918 | ↓ −566,517 |
| Bryan Wahl | 2,560,205 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Tarsus Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TARS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name TARS as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Andrew Goldberg | Independent Director | $310,284 |
| Bhaskar Chaudhuri | Independent Director | $315,728 |
| David E.I. Pyott | Independent Director | — |
| Katherine Goodrich | Independent Director | $306,728 |
| Rosemary Crane | Former director (through FY2025) | $2,889 |
| Scott Morrison | Independent Director | $316,728 |
| Wendy Yarno | Lead Independent Director | $394,339 |
| William J. Link | Independent Director | $313,228 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Scott Morrison | Director | 2026-06-12 | D | 2,954 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 1,928 | 63 | 121,348 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 10,572 | 62 | 655,147 | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-15 | D | 2,954 | 62 | 183,384 | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | D | 27,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | A | 27,881 | — | — | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-16 | D | 14,396 | 61 | 877,436 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 4,582 | 61 | 280,602 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 5,418 | 62 | 334,887 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-25 | — | 2,821 | — | — | 3 insiders, 3 accrual rows | ||
| William J. Link | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-01 | D | 4,601 | 74 | 339,830 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 5,387 | 80 | 430,960 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 1,590 | 80 | 127,200 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-02 | D | 10,000 | 80 | 800,600 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 85 | 135,150 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,387 | 85 | 457,895 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,386 | 90 | 484,740 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 90 | 143,100 | Common | Form 4 ↗ |
| Seshadri Neervannan | Chief Operating Officer | 2026-09-04 | D | 4,564 | 85 | 387,940 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 2,900 | 91 | 264,683 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 7,100 | 90 | 640,917 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 759 | 79 | 59,961 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 11,675 | 78 | 914,503 | Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-15 | — | 704 | — | — | 3 insiders, 3 accrual rows | ||
| William J. Link | Director | 2026-09-15 | D | 66 | 80 | 5,281 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-09-15 | A | 302 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Scott Morrison | Director | 2026-06-12 | D | 2,954 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | D | 2,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-12 | A | 2,954 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 1,928 | 63 | 121,348 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-15 | D | 10,572 | 62 | 655,147 | Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-15 | D | 2,954 | 62 | 183,384 | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | D | 27,881 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-15 | A | 27,881 | — | — | Common | Form 4 ↗ |
| Jeffrey Farrow | See Remarks | 2026-06-16 | D | 14,396 | 61 | 877,436 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 4,582 | 61 | 280,602 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-06-17 | D | 5,418 | 62 | 334,887 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 806 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 806 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 1,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhaskar Chaudhuri | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Goldberg | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 2,417 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Goodrich | Director | 2026-06-25 | A | 3,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-01 | D | 4,601 | 74 | 339,830 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 5,387 | 80 | 430,960 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-02 | D | 1,590 | 80 | 127,200 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-02 | D | 10,000 | 80 | 800,600 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 85 | 135,150 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,387 | 85 | 457,895 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 5,386 | 90 | 484,740 | Common | Form 4 ↗ |
| Elizabeth Yeu Lin | Chief Medical Officer | 2026-09-04 | D | 1,590 | 90 | 143,100 | Common | Form 4 ↗ |
| Seshadri Neervannan | Chief Operating Officer | 2026-09-04 | D | 4,564 | 85 | 387,940 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 2,900 | 91 | 264,683 | Common | Form 4 ↗ |
| Bobak Azamian | Director | 2026-09-04 | D | 7,100 | 90 | 640,917 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 759 | 79 | 59,961 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 11,675 | 78 | 914,503 | Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 201 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | D | 66 | 80 | 5,281 | Common | Form 4 ↗ |
| William J. Link | Director | 2026-09-15 | A | 201 | — | — | Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-09-15 | D | 302 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Yarno | Director | 2026-09-15 | A | 302 | — | — | Common | Form 4 ↗ |
| David E.I. Pyott | Director | 2026-09-15 | D | 201 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bobak Azamian | RSU | 2025-03-05 | — | — | 59,512 | — | $2,648,284 |
| Seshadri Neervannan | OPTION | 2025-03-05 | — | — | 30,628 | — | 895,011 |
| Aziz Mottiwala | RSU | 2025-03-05 | — | — | 22,098 | — | 983,361 |
| Jeffrey Farrow | OPTION | 2025-03-05 | — | — | 30,628 | — | 895,011 |
| Bobak Azamian | OPTION | 2025-03-05 | — | — | 90,736 | — | 2,651,487 |
| Jeffrey Farrow | RSU | 2025-03-05 | — | — | 20,089 | — | 893,961 |
| Seshadri Neervannan | RSU | 2025-03-05 | — | — | 20,089 | — | 893,961 |
| Bryan Wahl | RSU | 2025-03-05 | — | — | 20,089 | — | 893,961 |
| Bryan Wahl | OPTION | 2025-03-05 | — | — | 30,628 | — | 895,011 |
| Aziz Mottiwala | OPTION | 2025-03-05 | — | — | 33,691 | — | 984,518 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Bobak Azamian | $2,648,284 | $0 | $2,651,487 | 0.0% |
| Seshadri Neervannan | 893,961 | 0 | 895,011 | 0.0% |
| Aziz Mottiwala | 983,361 | 0 | 984,518 | 0.0% |
| Jeffrey Farrow | 893,961 | 0 | 895,011 | 0.0% |
| Bryan Wahl | 893,961 | 0 | 895,011 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bryan Wahl | RSU | 4,790 | — | $392,205 |
| Aziz Mottiwala | Option | 26,719 | 35.5 | — |
| Bobak Azamian | RSU | 11,300 | — | 925,244 |
| Bobak Azamian | RSU | 69,364 | — | 5,679,524 |
| Jeffrey Farrow | Option | 30,628 | 44.54 | — |
| Jeffrey Farrow | RSU | 24,060 | — | 1,970,033 |
| Bobak Azamian | RSU | 59,512 | — | 4,872,843 |
| Bryan Wahl | RSU | 7,508 | — | 614,755 |
| Seshadri Neervannan | RSU | 20,089 | — | 1,644,887 |
| Seshadri Neervannan | RSU | 7,508 | — | 614,755 |
| Aziz Mottiwala | RSU | 7,508 | — | 614,755 |
| Bryan Wahl | RSU | 21,527 | — | 1,762,631 |
| Jeffrey Farrow | RSU | 55,763 | — | 4,565,874 |
| Bobak Azamian | RSU | 33,950 | — | 2,779,826 |
| Aziz Mottiwala | RSU | 22,098 | — | 1,809,384 |
| Bryan Wahl | RSU | 20,089 | — | 1,644,887 |
| Seshadri Neervannan | RSU | 16,296 | — | 1,334,316 |
| Seshadri Neervannan | RSU | 5,097 | — | 417,342 |
| Bobak Azamian | RSU | 22,318 | — | 1,827,398 |
| Bobak Azamian | Option | 31,327 | 15 | — |
| Jeffrey Farrow | RSU | 7,508 | — | 614,755 |
| Bobak Azamian | Option | 9,630 | 19.59 | — |
| Jeffrey Farrow | Option | 54,466 | 14.62 | — |
| Bobak Azamian | Option | 77,034 | 35.5 | — |
| Bobak Azamian | Option | 90,736 | 44.54 | — |
| Seshadri Neervannan | Option | 26,719 | 35.5 | — |
| Seshadri Neervannan | Option | 15,037 | 15 | — |
| Bryan Wahl | Option | 23,907 | 35.5 | — |
| Aziz Mottiwala | Option | 33,691 | 44.54 | — |
| Bryan Wahl | Option | 13,377 | 15 | — |
| Seshadri Neervannan | Option | 30,628 | 44.54 | — |
| Bryan Wahl | Option | 30,628 | 44.54 | — |
| Aziz Mottiwala | Option | 4,082 | 19.59 | — |
| Aziz Mottiwala | RSU | 16,296 | — | 1,334,316 |
| Aziz Mottiwala | RSU | 24,060 | — | 1,970,033 |
| Bryan Wahl | Option | 4,082 | 19.59 | — |
| Seshadri Neervannan | RSU | 24,060 | — | 1,970,033 |
| Aziz Mottiwala | Option | 15,037 | 15 | — |
| Aziz Mottiwala | RSU | 4,790 | — | 392,205 |
| Jeffrey Farrow | Option | 26,719 | 35.5 | — |
| Jeffrey Farrow | RSU | 20,089 | — | 1,644,887 |
| Bryan Wahl | RSU | 14,497 | — | 1,187,014 |
| Seshadri Neervannan | Option | 4,345 | 19.59 | — |
Our executive compensation program emphasizes long-term value creation that correlates with the growth of sustainable long-term value for our stockholders, as well as motivates, retains, and rewards our NEOs.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-25 | 34,486,767 | 238,014 | 48,865 | 99.31% | Passed |
| 2025 | 2025-06-12 | 27,132,839 | 416,845 | 16,635 | 98.49% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-25 | 99.31%a |
| 2025 | 2025-06-12 | 98.49%b |
a. Approved under the standard stated in the filing — “Abstentions are not counted as a vote cast for or against the proposal and therefore have no effect on the outcome of the vote.”.
b. Approved under the standard stated in the filing — “Abstentions are not counted as a vote cast for or against the proposal and therefore have no effect on the outcome of the vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 26 : 1 |
|---|---|
| CEO total compensation | $6,617,979 |
| Median employee compensation | $251,525 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Wendy YarnoIndependent · Lead Independent Director · Compensation (Chair) · Commercial | $152,611 | $120,732 | $120,996 | $0 | $0 | $394,339 |
| Scott MorrisonIndependent · Audit (Chair) | 75,000 | 120,732 | 120,996 | 0 | 0 | 316,728 |
| Bhaskar ChaudhuriIndependent · Compensation · Science and Technology | 74,000 | 120,732 | 120,996 | 0 | 0 | 315,728 |
| William J. LinkIndependent · Compensation · Science and Technology | 71,500 | 120,732 | 120,996 | 0 | 0 | 313,228 |
| Andrew GoldbergIndependent · Audit · Nominating/Governance | 68,556 | 120,732 | 120,996 | 0 | 0 | 310,284 |
| Katherine GoodrichIndependent · Audit · Nominating/Governance | 65,000 | 120,732 | 120,996 | 0 | 0 | 306,728 |
| Rosemary CraneIndependent · Audit · Commercial · Departed during FY | 2,889 | — | — | 0 | 0 | 2,889 |
| Bobak AzamianEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| David E.I. PyottIndependent · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $241,728 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $509,556 |
| Equity awards (grant-date value) | $724,392 |
| All other compensation | $0 |
| Total cost of the board | $1,233,948 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Tarsus Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Tarsus Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ocular Therapeutix, Inc. | 2025 | Pravin Dugel | $819,200 | $18,608,000 | $15,567,000 | $0 | $35,946,958 |
| 2 | Harrow, Inc. | 2025 | Mark Baum | 754,910 | 22,294,873 | 0 | 542,491 | 23,606,274 |
| 3 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 4 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 5 | Supernus Pharmaceuticals. Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 6 | Kiniksa Pharmaceuticals, Ltd. | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 7 | Mirum Pharmaceuticals, Inc. | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 8 | Mannkind Corp. | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 9 | Ardelyx, Inc. | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 10 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 11 | Arcutis Biotherapeutics, Inc. | 2025 | Todd Franklin Watanabe | 713,333 | 2,067,190 | 3,848,958 | 579,584 | 7,223,065 |
| 12 | Tarsus Pharmaceuticals | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 13 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 14 | Evolus, Inc. | 2025 | David Moatazedi | 775,000 | 3,886,569 | 1,296,697 | 429,000 | 6,412,214 |
| 15 | Aurinia Pharmaceuticals, Inc. | 2025 | Peter Greenleaf | 822,877 | 1,965,321 | 2,193,189 | 864,021 | 5,858,590 |
| 16 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Tarsus Pharmaceuticals | 108% | Options 50 · RSU 50 | No | Pay Governance |
| Arcutis Biotherapeutics, Inc. | 125% | not disclosed | No | Pay Governance LLC |
| Ardelyx, Inc. | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Aurinia Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | WTW |
| Catalyst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Day One Biopharmaceuticals, Inc. | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Evolus, Inc. | 55% | not disclosed | No | Radford, an Aon Company |
| Harrow, Inc. | 100% | not disclosed | No | Mercer, Inc. |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Kiniksa Pharmaceuticals, Ltd. | not disclosed | Option 50 · RSU 25 · PSU 25 | not disclosed | Compensia, Inc. |
| Mannkind Corp. | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| Mirum Pharmaceuticals, Inc. | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Ocular Therapeutix, Inc. | 145% | not disclosed | No | Aon |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Supernus Pharmaceuticals. Inc. | not disclosed | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Bobak Azamian | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 6,617,979. Filing ↗machine: span 448592–448601 |
| 2 | Section 01, Aziz Mottiwala | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,789,529. Filing ↗machine: span 483207–483216 |
| 3 | Section 01, Jeffrey Farrow | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,677,617. Filing ↗machine: span 460302–460311 |
| 4 | Section 01, Seshadri Neervannan | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,628,172. Filing ↗machine: span 471815–471824 |
| 5 | Section 01, Bryan Wahl | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 2,560,205. Filing ↗machine: t21 · r17 · c22 · span 491808–491817 |
| 6 | Section 03, Bobak Azamian RSU | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 520278–520287 |
| 7 | Section 03, Seshadri Neervannan OPTION | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 548798–548805 |
| 8 | Section 03, Aziz Mottiwala RSU | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 569116–569123 |
| 9 | Section 03, Jeffrey Farrow OPTION | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 532520–532527 |
| 10 | Section 03, Bobak Azamian OPTION | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 516224–516233 |
| 11 | Section 03, Jeffrey Farrow RSU | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 536572–536579 |
| 12 | Section 03, Seshadri Neervannan RSU | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 552850–552857 |
| 13 | Section 03, Bryan Wahl RSU | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 585490–585497 |
| 14 | Section 03, Bryan Wahl OPTION | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 581438–581445 |
| 15 | Section 03, Aziz Mottiwala OPTION | DEF 14A | 1900-01-01 | 0001819790-26-000028 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 565064–565071 |
| 16 | Section 07, pay ratio | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “CEO Pay Ratio”. As printed: 26 : 1. Filing ↗machine: span 862197–862199 |
| 17 | Section 08, Wendy Yarno | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 394,339. Filing ↗machine: t10 · r7 · c11 · span 242724–243029 |
| 18 | Section 08, Scott Morrison | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 316,728. Filing ↗machine: t10 · r6 · c11 · span 240826–241131 |
| 19 | Section 08, Bhaskar Chaudhuri | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 315,728. Filing ↗machine: t10 · r2 · c11 · span 233180–233511 |
| 20 | Section 08, William J. Link | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 313,228. Filing ↗machine: t10 · r5 · c11 · span 238942–239247 |
| 21 | Section 08, Andrew Goldberg | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 310,284. Filing ↗machine: t10 · r3 · c11 · span 235134–235439 |
| 22 | Section 08, Katherine Goodrich | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 306,728. Filing ↗machine: t10 · r4 · c11 · span 237039–237344 |
| 23 | Section 08, Rosemary Crane | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 2,889. Filing ↗machine: t10 · r8 · c2 · span 243640–243879 |
| 24 | Section 08, Bobak Azamian | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 08, David E.I. Pyott | DEF 14A | 2026-04-28 | 0001819790-26-000028 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 02, Scott Morrison 2026-06-12 | Form 4 | 2026-06-16 | 0001662426-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Andrew Goldberg 2026-06-12 | Form 4 | 2026-06-16 | 0001827722-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Andrew Goldberg 2026-06-12 | Form 4 | 2026-06-16 | 0001827722-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Wendy Yarno 2026-06-12 | Form 4 | 2026-06-16 | 0001181186-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Wendy Yarno 2026-06-12 | Form 4 | 2026-06-16 | 0001181186-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Katherine Goodrich 2026-06-12 | Form 4 | 2026-06-16 | 0002044770-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Katherine Goodrich 2026-06-12 | Form 4 | 2026-06-16 | 0002044770-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Bhaskar Chaudhuri 2026-06-12 | Form 4 | 2026-06-16 | 0001458643-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Bhaskar Chaudhuri 2026-06-12 | Form 4 | 2026-06-16 | 0001458643-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, William J. Link 2026-06-12 | Form 4 | 2026-06-16 | 0001228684-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, William J. Link 2026-06-12 | Form 4 | 2026-06-16 | 0001228684-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Scott Morrison 2026-06-12 | Form 4 | 2026-06-16 | 0001662426-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, William J. Link 2026-06-15 | Form 4 | 2026-06-17 | 0001228684-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, William J. Link 2026-06-15 | Form 4 | 2026-06-17 | 0001228684-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Katherine Goodrich 2026-06-15 | Form 4 | 2026-06-17 | 0002044770-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Jeffrey Farrow 2026-06-15 | Form 4 | 2026-06-17 | 0001405253-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Jeffrey Farrow 2026-06-15 | Form 4 | 2026-06-17 | 0001405253-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Jeffrey Farrow 2026-06-16 | Form 4 | 2026-06-17 | 0001405253-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Bobak Azamian 2026-06-17 | Form 4 | 2026-06-22 | 0001827672-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Bobak Azamian 2026-06-17 | Form 4 | 2026-06-22 | 0001827672-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, William J. Link 2026-06-25 | Form 4 | 2026-06-29 | 0001228684-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, William J. Link 2026-06-25 | Form 4 | 2026-06-29 | 0001228684-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, William J. Link 2026-06-25 | Form 4 | 2026-06-29 | 0001228684-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, David E.I. Pyott 2026-06-25 | Form 4 | 2026-06-29 | 0001051578-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, David E.I. Pyott 2026-06-25 | Form 4 | 2026-06-29 | 0001051578-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, David E.I. Pyott 2026-06-25 | Form 4 | 2026-06-29 | 0001051578-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Wendy Yarno 2026-06-25 | Form 4 | 2026-06-29 | 0001181186-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Wendy Yarno 2026-06-25 | Form 4 | 2026-06-29 | 0001181186-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Wendy Yarno 2026-06-25 | Form 4 | 2026-06-29 | 0001181186-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Bhaskar Chaudhuri 2026-06-25 | Form 4 | 2026-06-29 | 0001458643-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Bhaskar Chaudhuri 2026-06-25 | Form 4 | 2026-06-29 | 0001458643-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Scott Morrison 2026-06-25 | Form 4 | 2026-06-29 | 0001662426-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Scott Morrison 2026-06-25 | Form 4 | 2026-06-29 | 0001662426-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Andrew Goldberg 2026-06-25 | Form 4 | 2026-06-29 | 0001827722-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Andrew Goldberg 2026-06-25 | Form 4 | 2026-06-29 | 0001827722-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Katherine Goodrich 2026-06-25 | Form 4 | 2026-06-29 | 0002044770-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Katherine Goodrich 2026-06-25 | Form 4 | 2026-06-29 | 0002044770-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Elizabeth Yeu Lin 2026-09-01 | Form 4 | 2026-09-03 | 0001842190-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Elizabeth Yeu Lin 2026-09-02 | Form 4 | 2026-09-03 | 0001842190-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Elizabeth Yeu Lin 2026-09-02 | Form 4 | 2026-09-03 | 0001842190-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Bobak Azamian 2026-09-02 | Form 4 | 2026-09-03 | 0001827672-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Elizabeth Yeu Lin 2026-09-04 | Form 4 | 2026-09-09 | 0001842190-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Elizabeth Yeu Lin 2026-09-04 | Form 4 | 2026-09-09 | 0001842190-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Elizabeth Yeu Lin 2026-09-04 | Form 4 | 2026-09-09 | 0001842190-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Elizabeth Yeu Lin 2026-09-04 | Form 4 | 2026-09-09 | 0001842190-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Seshadri Neervannan 2026-09-04 | Form 4 | 2026-09-09 | 0001827584-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Bobak Azamian 2026-09-04 | Form 4 | 2026-09-09 | 0001827672-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Bobak Azamian 2026-09-04 | Form 4 | 2026-09-09 | 0001827672-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, William J. Link 2026-09-15 | Form 4 | 2026-09-17 | 0001228684-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, William J. Link 2026-09-15 | Form 4 | 2026-09-17 | 0001228684-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, David E.I. Pyott 2026-09-15 | Form 4 | 2026-09-17 | 0001051578-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, William J. Link 2026-09-15 | Form 4 | 2026-09-17 | 0001228684-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, William J. Link 2026-09-15 | Form 4 | 2026-09-17 | 0001228684-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, William J. Link 2026-09-15 | Form 4 | 2026-09-17 | 0001228684-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Wendy Yarno 2026-09-15 | Form 4 | 2026-09-17 | 0001181186-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Wendy Yarno 2026-09-15 | Form 4 | 2026-09-17 | 0001181186-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, David E.I. Pyott 2026-09-15 | Form 4 | 2026-09-17 | 0001051578-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 06, 2026 vote | Form 8-K | 2026-06-29 | 0001819790-26-000043 | Item 5.07 · say-on-pay result. As reported: 99.31% (votes for as printed: 34,486,767). Filing ↗ |
| 84 | Section 06, 2025 vote | Form 8-K | 2025-06-18 | 0001819790-25-000100 | Item 5.07 · say-on-pay result. As reported: 98.49% (votes for as printed: 27,132,839). Filing ↗ |
| 85 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 86 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 87 | Section 09b board cost (computed) | Computed | — | — | Cash 509,556 + equity 724,392 + all other 0 = 1,233,948, summed across the director compensation table rows.machine: formula: Σ = 1,233,948 |
| 88 | Ocular Therapeutix, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053176 | CEO total compensation as printed in Ocular Therapeutix, Inc.'s own proxy. As printed: 35,946,958. Filing ↗machine: t128 · r3 · c15 · span 574379–574389 |
| 89 | Harrow, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001493152-26-018912 | CEO total compensation as printed in Harrow, Inc.'s own proxy. As printed: 23,606,274. Filing ↗machine: t87 · r1 · c26 · span 386989–386999 |
| 90 | Rhythm Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 91 | SpringWorks Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-04 | 0001104659-25-032187 | CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. Filing ↗machine: r1 · c47 · span 623184–623194 |
| 92 | Supernus Pharmaceuticals. Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals. Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 93 | Kiniksa Pharmaceuticals, Ltd., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001104659-26-044410 | CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. Filing ↗ |
| 94 | Mirum Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 95 | Mannkind Corp., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145613 | CEO total compensation as printed in Mannkind Corp.'s own proxy. As printed: 9,300,485. Filing ↗machine: t24 · r5 · c27 · span 606612–606621 |
| 96 | Ardelyx, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx, Inc.'s own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 97 | Catalyst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗ |
| 98 | Arcutis Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001787306-26-000028 | CEO total compensation as printed in Arcutis Biotherapeutics, Inc.'s own proxy. As printed: 7,223,065. Filing ↗machine: r2 · c42 · span 646815–646824 |
| 99 | Tarsus Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001819790-26-000028 | CEO total compensation as printed in Tarsus Pharmaceuticals's own proxy. As printed: 6,617,979. Filing ↗machine: span 448592–448601 |
| 100 | Day One Biopharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001140361-25-013462 | CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333 |
| 101 | Evolus, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001570562-26-000059 | CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. Filing ↗machine: span 499358–499367 |
| 102 | Aurinia Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001600620-26-000039 | CEO total compensation as printed in Aurinia Pharmaceuticals, Inc.'s own proxy. As printed: 5,858,590. Filing ↗machine: r2 · c48 · span 429605–429614 |
| 103 | Ironwood Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191 |
| 104 | Section 10a, Kiniksa Pharmaceuticals, Ltd. reciprocity | DEF 14A | — | 0001104659-26-044410 | Kiniksa Pharmaceuticals, Ltd.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 105 | Section 10a, Mannkind Corp. reciprocity | DEF 14A | — | 0001193125-26-145613 | Mannkind Corp.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 106 | Section 10a, Catalyst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 107 | Section 10a, Mirum Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 108 | Section 10a, Ironwood Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-050325 | Ironwood Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 109 | Section 10a, Rhythm Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 110 | Section 10a, SpringWorks Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-032187 | SpringWorks Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 111 | Section 10a, Harrow, Inc. reciprocity | DEF 14A | — | 0001493152-26-018912 | Harrow, Inc. names Tarsus Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 112 | Section 10a, Arcutis Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0001787306-26-000028 | Arcutis Biotherapeutics, Inc. names Tarsus Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 113 | Section 10a, Ardelyx, Inc. reciprocity | DEF 14A | — | 0001140361-26-017800 | Ardelyx, Inc. names Tarsus Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 114 | Section 10a, Day One Biopharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-25-013462 | Day One Biopharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 115 | Section 10a, Evolus, Inc. reciprocity | DEF 14A | — | 0001570562-26-000059 | Evolus, Inc. names Tarsus Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 116 | Section 10a, Ocular Therapeutix, Inc. reciprocity | DEF 14A | — | 0001104659-26-053176 | Ocular Therapeutix, Inc. names Tarsus Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 117 | Section 10a, Supernus Pharmaceuticals. Inc. reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals. Inc.'s most recent proxy was read; its disclosed peer group does not include Tarsus Pharmaceuticals. Filing ↗ |
| 118 | Section 10a, Aurinia Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001600620-26-000039 | Aurinia Pharmaceuticals, Inc. names Tarsus Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.